Protocol Ledger

NCT05721573 · Phase II/III · COMPLETED

A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis

Interventional Phase II/III clinical trial protocol NCT05721573 sponsored by Abcuro in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-02-28 Enrollment: 272 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05721573
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)272 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05721573
Protocol FieldVerified Registry Value
NCT IdentifierNCT05721573
Consolidated Lead SponsorAbcuro
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusCOMPLETED
Registered Enrollment272 participants (ACTUAL)
Registered Start Date2023-02-28
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI